Asset Details
Do you wish to reserve the book?
Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial
Do you wish to request the book?
Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial
2006
Overview
Early reperfusion of occluded coronary arteries has significantly reduced early mortality and improved the long-term prognosis of patients with an acute myocardial infarction. However, the development of postinfarction heart failure remains a major challenge. Initial experimental studies indicated that mononuclear progenitor cells derived from the bone marrow may contribute to the functional regeneration of freshly infarcted myocardium and increase neovascularization of ischemic areas. A number of clinical pilot trials have now transferred the experimental approach into the clinical arena, aiming at regenerating myocardial function with infusion of bone-marrow-derived progenitor cells in patients after an acute myocardial infarction. While these initial trials using intracoronary infusion of bone-marrow-derived progenitor cells indeed suggested that such a strategy appears to be feasible and safe in patients with an acute myocardial infarction, there is definitely a pressing need for a proof-of-concept study documenting a potentially beneficial effect of progenitor cell therapy on cardiac function.
Publisher
Nature Publishing Group
Subject
/ Cardiac Output, Low - etiology
/ Cardiac Output, Low - physiopathology
/ Cardiac Output, Low - therapy
/ Humans
/ Multicenter Studies as Topic
/ Myocardial Infarction - complications
/ Myocardial Infarction - physiopathology
/ Myocardial Infarction - therapy
